Butterfly Network, Inc. develops semiconductor-based ultrasound devices, programmable cloud software and AI for medical imaging and sensing. Its Ultrasound-on-Chip technology underpins handheld whole-body ultrasound systems such as Butterfly iQ, iQ+ and iQ3, along with enterprise workflow software including Compass AI and developer tools such as Butterfly Garden.
Company news commonly covers financial results, point-of-care ultrasound adoption, FDA-cleared AI tools such as its Gestational Age Tool, U.S. and international sales channels, and platform initiatives. Updates also address Butterfly Embedded, the company’s licensing and co-development effort for applying its ultrasound chip and software platform in partner-built products, as well as board and leadership changes tied to medtech, clinical strategy and commercialization.
Butterfly Network (NYSE: BFLY) announced that Mendaera’s Focalist system is now commercially available with its Ultrasound-on-Chip imaging technology. The offering uses a customized Butterfly iQ3 probe and marks the first Butterfly Embedded partner technology to reach the market. The companies previously announced their collaboration through the Embedded program.
Mendaera’s FDA-cleared Focalist combines handheld robotics, real-time imaging and guidance software for image-guided needle procedures, including vascular access, regional nerve blocks and organ access. Its U.S. clearance covers guidance for instrument placement during diagnostic or therapeutic procedures in pediatric and adult patients. Mendaera said Butterfly’s programmable imaging platform opens a path toward AI-enabled image interpretation and robotic action.
Butterfly Network (BFLY)/b) will participate in the Morgan Stanley 24th Annual Global Healthcare Conference in New York City on September 15, 2026.President and CEO Joseph DeVivo, CFO John Doherty, and Chief Accounting Officer Megan Carlson will attend, host one-on-one investor meetings, and join a fireside chat at 10:00 AM ET. A live webcast of the fireside chat will be accessible via the Events & Presentations section of Butterfly's investor website.
Butterfly Network (NYSE: BFLY) announced a multi-year licensing agreement with Merge Labs through Butterfly Embedded™, granting Merge access to Butterfly’s Poseidon Family Ultrasound-on-Chip™ technology to develop ultrasound-based brain-computer interfaces (BCI). The agreement includes upfront and milestone-based license payments, hardware purchase commitments, technology access fees, and expected ongoing royalties to Butterfly on future commercial sales. Butterfly will act as Merge’s exclusive CMOS-MEMS chip-based ultrasound partner while retaining the right to license its platform to other BCI companies. Merge launched in January 2026 with $252 million in seed funding to pursue its mission of bridging biological and artificial intelligence.
Butterfly Network (NYSE:BFLY) announced that Dr. Erica Schwartz has been confirmed as director of the U.S. Centers for Disease Control and Prevention (CDC). She has served on Butterfly Network’s Board of Directors since 2021 and stepped down from the Board effective August 5, 2026 ahead of assuming her new role.
President, CEO and Chairman Joseph DeVivo thanked Dr. Schwartz for her clinical expertise and service, noting her lasting impact on the company. Butterfly Network also highlights its Ultrasound-on-Chip™ technology, portable iQ3™ device, Compass AI™ workflow solution, Butterfly Garden™ developer platform, and Butterfly Embedded™ licensing and co-development business.
TELA Bio (NASDAQ: TELA) announced that its Board of Directors has appointed Heather Getz as Chief Executive Officer and Director, effective August 4, 2026. Chairman Joseph Capper said the Board selected Getz to guide TELA Bio’s next phase of growth, commercial execution and value creation for patients, surgeons, shareholders and employees.
According to TELA Bio, Getz most recently served as Executive Vice President and Chief Financial and Operations Officer at Butterfly Network (NYSE: BFLY), where she implemented strategic, capital allocation and cash runway changes. Previously, as Executive Vice President and Chief Financial and Administrative Officer at BioTelemetry, the company’s market capitalization increased from $50 million to $2.8 billion before its acquisition by Philips Healthcare in 2021. TELA Bio expressed gratitude to co‑founder and outgoing leader Antony Koblish for developing OviTex and helping establish its position in soft‑tissue reconstruction.
Butterfly Network (NYSE:BFLY) reported Q2 2026 revenue of $32.6 million, up 39% year over year, with U.S. revenue of $27.6 million (+57%) and international revenue of $5.0 million (-14%). Gross margin rose to 71.4%, driven by higher-margin Butterfly Embedded licensing and lower software amortization.
Operating expenses increased 19% to $37.0 million. Net loss was $12.9 million (EPS $(0.05)), while adjusted EBITDA loss improved 78% to $1.4 million. Cash and equivalents were $124.7 million. Butterfly raised 2026 revenue guidance to $119–$123 million and now expects a full-year adjusted EBITDA loss of $19–$23 million. The company highlighted momentum in Butterfly Embedded, Compass AI enterprise software, medical education, Home & Community Care commercialization, and new regulatory authorization in Brazil.
Science Corporation, a neural engineering and brain-computer interface company, appointed Nevada Sanchez as Executive Vice President of Engineering, reporting to CEO and co-founder Max Hodak. Sanchez co-founded Butterfly Network (NYSE: BFLY), where he led development of the first ultrasound system on a chip and helped build a globally deployed semiconductor-based medical imaging platform.
According to Science, the hire follows its $230 million Series C raise and coincides with the European commercial launch of PRIMA, a BCI retinal implant, and accelerated work on its Biohybrid neural interface, Vessel perfusion programs, and Science Foundry expansion. Science states that PRIMA is the only treatment to have successfully restored form vision in clinical trial patients blinded by late-stage macular degeneration, has New England Journal of Medicine results, a Time cover feature, and a CE mark enabling commercial availability in 30 European countries, with an FDA process underway. Sanchez holds multiple MIT degrees and key academic honors.
Butterfly Network (NYSE: BFLY) will release its second quarter 2026 financial results on Thursday, July 30, 2026, at 8:00 a.m. ET. President and CEO Joseph DeVivo and CFO John Doherty will host a conference call and live webcast before the market opens to review performance and operations.
The listen-only webcast will be accessible via Butterfly’s Investor Relations Events & Presentations page. Telephone access is available using U.S. local and toll-free numbers with access code 424023. An archived webcast and telephone replay, using access code 941825, will be available through August 6, 2026.
Butterfly Network (NYSE:BFLY) announced commercial availability of its Butterfly iQ+ and iQ3 handheld ultrasound devices and mobile app in Brazil through authorized distribution partners.
The move targets Brazil's large and fast-growing ultrasound market, aiming to expand point-of-care imaging across hospitals, clinics, emergency care, and underserved rural communities.
Butterfly Network (NYSE:BFLY) highlighted partner Aleph Neuro, a brain-computer interface research lab using Butterfly's Ultrasound-on-Chip™ platform. Aleph publicly shared what it describes as a breakthrough in non-invasive brain imaging, posting high-resolution 3D images of the human brain captured from outside the skull.
According to Butterfly, Aleph participates in the Butterfly Embedded™ licensing and co-development program. Aleph’s work aims to deliver “MRI-level detail” without drilling or an MRI machine. Butterfly noted that Aleph’s news follows a full-body ultrasound CT scanner unveiling from Embedded partner Midjourney, underscoring broader Ultrasound-on-Chip™ applications.